This analysis reveals angioedema risk linked to thrombolytics and ACE inhibitors, suggesting a potential concern in certain patients.
Background Thrombolytic therapy is linked to angioedema, a serious adverse event, with higher risk when co-administered with renin-angiotensin-aldosterone system inhibitors (RAAS-i), particularly ACE inhibitors. However, this interaction remains incompletely characterized.
No takes yet. Share an insight, caveat, or question.
Kannan Sridharan (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: